Receipt #4.
Attorney Docket No. 4099-0003.31**FILE COPY**

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C., 20231, on:

Date: 3-14-01By: Lynnea B. Anderson**PATENT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF:

Allan S. Lau et al.

SERIAL No.: 09/772,109

FILED: January 26, 2001

FOR: **HIGH LEVEL CYTOKINE
PRODUCTION WITH ENHANCED
CELL VIABILITY**

EXAMINER: Unknown

ART UNIT: 1644

Request for Corrected Filing Receipt

Application Processing Division
Customer Correction Branch
Assistant Commissioner for Patents
Washington, D.C. 20231

1. Attached is a copy of an official filing receipt received from the U.S. Patent and Trademark Office for which a corrected filing receipt is respectfully requested.
2. There is an error in the following data, which was:

- ☒ incorrectly entered and/or
☐ omitted

	ERROR IN	CORRECT DATA
1. <input checked="" type="checkbox"/>	Applicant name	Natalya Ossina
2. <input type="checkbox"/>	Applicant address	
3. <input type="checkbox"/>	Title	
4. <input type="checkbox"/>	Filing Date	
5. <input type="checkbox"/>	Serial Number	

Respectfully submitted,

Linda R. Judge

Registration No. 42,702

Date: March 14, 2001**Correspondence Address:**

Customer No. 22918

Phone: 650 324-0880

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov



APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/772,109	01/26/2001	1644	526	4099-0003.31	5	19	3

CONFIRMATION NO. 8965

FILING RECEIPT



OC000000005843217

22918
IOTA PI LAW GROUP
350 CAMBRIDGE AVENUE SUITE 250
P O BOX 60850
PALO ALTO, CA 94306-0850

COPY

Date Mailed: 03/09/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).


RECEIVED

Applicant(s)

Natalya Allan S. Lau, Fremont, CA;
Natalya Ossina, Albany, CA;
Kenneth Hoyt, San Rafael, CA;

JUL 06 2001

TECH CENTER 1600/2000



Continuing Data as Claimed by Applicant

THIS APPLICATION IS A CIP OF 09/657,881 09/08/2000
WHICH CLAIMS BENEFIT OF 60/152,854 09/08/1999

Foreign Applications

If Required, Foreign Filing License Granted 03/08/2001


Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title



High level cytokine production with enhanced cell viability

Preliminary Class

530

Data entry by : TEKLEMICHAEL, MULU

Team : OIPE

Date: 03/09/2001



**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231

FILE COPY**UNITED STATES PATENT AND TRADEMARK OFFICE**

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov



Bib Data Sheet

CONFIRMATION NO. 8965

SERIAL NUMBER 09/772,109	FILING DATE 01/26/2001 RULE	CLASS	GROUP ART UNIT 1647	ATTORNEY DOCKET NO. 4099-0003.31
------------------------------------	---	--------------	-------------------------------	--

APPLICANTS

Allan S. Lau, Fremont, CA;
Natalya Ossina, Albany, CA;
Kenneth Hoyt, San Rafael, CA;

RECEIVED**JUL 06 2001****TECH CENTER 1600/2900****** CONTINUING DATA *******

THIS APPLICATION IS A CIP OF 09/657,881 09/08/2000
WHICH CLAIMS BENEFIT OF 60/152,854 09/08/1999

**** FOREIGN APPLICATIONS *********IF REQUIRED, FOREIGN FILING LICENSE GRANTED.. SMALL ENTITY ******** 03/08/2001**

Foreign Priority claimed <input type="checkbox"/> yes <input checked="" type="checkbox"/> no	STATE OR COUNTRY CA	SHEETS DRAWING 5	TOTAL CLAIMS 19	INDEPENDENT CLAIMS 3
35 USC 119 (a-d) conditions met <input type="checkbox"/> yes <input checked="" type="checkbox"/> no <input type="checkbox"/> Met after Allowance				
Verified and Acknowledged Examiner's Signature <i>[Signature]</i> Initials <i>[Initials]</i>				

ADDRESS

22918

TITLE

High level cytokine production with enhanced cell viability

FILING FEE RECEIVED 591	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:	<input type="checkbox"/> All Fees
		<input type="checkbox"/> 1.16 Fees (Filing)
		<input type="checkbox"/> 1.17 Fees (Processing Ext. of time)
		<input type="checkbox"/> 1.18 Fees (Issue)
		<input type="checkbox"/> Other _____
		<input type="checkbox"/> Credit